Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CD20

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    335 result(s) found for: CD20. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-000647-12 Sponsor Protocol Number: ML28881 Start Date*: 2013-06-09
    Sponsor Name:ROCHE S.p.A.
    Full Title: A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously u...
    Medical condition: CD20+ diffuse large B-cell lymphoma or CD20+ follicular non-Hodgkin’s lymphoma grade 1, 2 or 3a
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001589-34 Sponsor Protocol Number: LNH03-7B Start Date*: 2007-06-05
    Sponsor Name:GELA Group
    Full Title: Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma
    Medical condition: CD20+ diffuse large B-cell lymphoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016136-12 Sponsor Protocol Number: RIMCEB-09 Start Date*: 2010-01-27
    Sponsor Name:Czech Lymphoma Research Organization s.r.o. (CLRO)
    Full Title: PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemothe...
    Medical condition: Prognosis of high-risk patients with diffuse large B-cell lymphoma is still less then optimal. According to revised Int. Prognostic Index, patients with 3-5 adverse prognostic factors have only abo...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014641-88 Sponsor Protocol Number: STP-LYM-01-V01 Start Date*: 2010-01-14
    Sponsor Name:Medizinische Fakultaet der Technischen Universitaet Muenchen
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 posit...
    Medical condition: CD20 positive chronic lymphocytic leukemia (CLL) low and high grade non-Hodgkin´s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004110-17 Sponsor Protocol Number: BO18414 Start Date*: 2005-03-29
    Sponsor Name:Roche Products Limited
    Full Title: Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMAb 2H7 in patients with follicular non Hodgkin’s lymphoma
    Medical condition: follicular non-Hodgkin’s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006137-41 Sponsor Protocol Number: VAL-518-HEE-0200-S Start Date*: 2007-08-07
    Sponsor Name:Medizinische Fakultät der Technischen Universität München, vertreten durch den Dekan
    Full Title: Prospective, randomized, open, 2-arm national multi-center study to evaluate the value of Rituximab in humoral chronic rejection after renal transplantation
    Medical condition: Renal transplant patients beyond 1 year post Tx, suffering from CAN and histologically proven C4d deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009256-20 Sponsor Protocol Number: OMB110928 Start Date*: 2009-12-23
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) SE (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) HU (Completed) PL (Prematurely Ended) DE (Prematurely Ended) AT (Completed) EE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014722-42 Sponsor Protocol Number: HO105 Start Date*: 2010-07-07
    Sponsor Name:HOVON Foundation
    Full Title: Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study
    Medical condition: Primary Central Nervous system Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036685 Primary central nervous system lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-016026-13 Sponsor Protocol Number: O-ESHAP-LH-2009 Start Date*: 2010-05-18
    Sponsor Name:FUNDACION GELTAMO
    Full Title: Estudio de fase II de uso de anticuerpo monoclonal anti-CD20 (ofatumumab) más ESHAP seguido de trasplante autólogo de progenitores hemopoyéticos para el tratamiento de linfoma de Hodgkin clásico en...
    Medical condition: EL PRESENTE ESTUDIO PROPONE TRATAR PACIENTES CON LINFOMA DE HODGKIN CLASICO REFRACTARIO, EN RESPUESTA PARCIAL O RECAIDA CON QUIMIOTERAPIA SEGUN DOSIS ESTANDAR DE ESHAP EN COMBINACION CON OFATUMUMAB...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003849-18 Sponsor Protocol Number: CMC-R-GEMOX Start Date*: 2012-06-07
    Sponsor Name:LYSARC
    Full Title: A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM ...
    Medical condition: CD20 and CD22 positive diffuse large B-cell lymphoma in first or second relapse or refractory to first and/or second line treatment
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017995-26 Sponsor Protocol Number: LNH09-7B Start Date*: 2010-04-01
    Sponsor Name:GELARC
    Full Title: PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA
    Medical condition: Diffuse large B Cell lymphoma, Code EUDRA 10003899
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003230-17 Sponsor Protocol Number: MO28457 Start Date*: 2013-02-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DI...
    Medical condition: The target population will consist of adults with previously untreated CD20+ DLBCL or CD20+ follicular NHL Grade 1, 2 or 3a, according to the WHO classification system.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) NL (Completed) IT (Completed) PT (Completed) SE (Completed) AT (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-005506-56 Sponsor Protocol Number: MabionCD20-002NHL Start Date*: 2014-11-20
    Sponsor Name:MABION S.A.
    Full Title: Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab by Hoffman-La Roche) in Patients with Diffuse Large B-cell Lymphoma
    Medical condition: CD20 positive Diffuse Large B cell Lymphoma (DLBCL) patients diagnosed according to WHO classification of lymphomas, eligible for rituximab treatment according to MabThera SmPC with life expectance...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023407-95 Sponsor Protocol Number: MO25455 Start Date*: 2011-10-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lympho...
    Medical condition: Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marg...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013103 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) SK (Completed) LT (Completed) HU (Completed) FR (Completed) ES (Completed) SI (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002344-26 Sponsor Protocol Number: R-GEMOX Start Date*: 2005-07-07
    Sponsor Name:GELA
    Full Title: GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLAN...
    Medical condition: Refractory/relapsed patients with CD 20 positive large B-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003091-19 Sponsor Protocol Number: GOTEL-FL1LC-0701 Start Date*: 2007-11-14
    Sponsor Name:GOTEL (Grupo Oncológico para el Tratamiento y Estudio de Los linfomas)
    Full Title: "Tratamiento de consolidación con Y90-Ibritumomab Tiuxetan en Pacientes con Linfoma Folicular de Alto Riesgo, en respuesta parcial o completa a Quimioterapia de Inducción con R-CHOP"
    Medical condition: Linfoma Folicular CD20+, grado 1-3a, según la clasificación de la OMS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004774-85 Sponsor Protocol Number: IDEC 102-12 Start Date*: 2005-04-13
    Sponsor Name:Biogen Idec Inc
    Full Title: A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens
    Medical condition: Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002103-32 Sponsor Protocol Number: 50-03B Start Date*: 2005-03-02
    Sponsor Name:GELA-Recherche Clinique
    Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,...
    Medical condition: CD 20 positive diffuse large B cell lymphoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000905-26 Sponsor Protocol Number: CoVaCan-01 Start Date*: 2021-03-31
    Sponsor Name:Department of Oncology, Uppsala University Hospita
    Full Title: Immune response to Covid-19 vaccination in patients with immune modulatory treatment for cancer
    Medical condition: Immune response to Covid-19 vaccination of patients with immune modulatory treatment for cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003460-19 Sponsor Protocol Number: BO21003 Start Date*: 2009-05-12
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.
    Medical condition: Patients with relapsed CD20+ indolent NHL will be enrolled (Relapsed defined as; relapsed indolent lymphoma with documented history of response [CR, CRu, or PR) of≥6 months in duration from the com...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) SE (Completed) NL (Completed) DK (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 16:15:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA